New(er) to the crew: Remimazolam, Sugammadex, & Novel Opioids

<p>Today we’re diving into the future of anesthesia pharmacology with three major topics changing perioperative practice: <strong>Remimazolam, Sugammadex, and Novel Opioids</strong>. These medications were designed to improve what we care about most—faster recovery, safer profiles, more predictable pharmacokinetics, and better patient outcomes.</p><p>In this episode, we break down:</p><p>✔️ <strong>Remimazolam</strong> – the ultra-short acting benzodiazepine with esterase metabolism, rapid recovery, and potential hemodynamic advantages over propofol<br>✔️ <strong>Sugammadex</strong> – the game-changing reversal agent for rocuronium and vecuronium, including dosing, mechanisms, risks, and board pearls<br>✔️ <strong>Novel Opioids</strong> – including biased agonists like <strong>oliceridine</strong>, and the ongoing search for analgesia with fewer side effects</p><p>We also cover:<br>🎯 High-yield NBCRNA/NCE pharmacology points<br>🎯 Clinical pros and cons of each drug<br>🎯 Real-world barriers like cost, adoption, and safety concerns<br>🎯 How to think like an anesthesia provider—not just memorize drugs</p><p>Whether you’re an SRNA, CRNA, resident, or anesthesia nerd who loves pharmacology, this episode will help you connect the science to clinical practice.</p>